BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharma Journalist - ECPv6.16.1//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:https://www.pharmajournalist.com
X-WR-CALDESC:Events for Pharma Journalist
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Asia/Kolkata
BEGIN:STANDARD
TZOFFSETFROM:+0530
TZOFFSETTO:+0530
TZNAME:IST
DTSTART:20190101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20201118
DTEND;VALUE=DATE:20201219
DTSTAMP:20260515T132444
CREATED:20200930T094828Z
LAST-MODIFIED:20210118T080755Z
UID:27309-1605657600-1608335999@www.pharmajournalist.com
SUMMARY:CPhI & P-MEC China Virtual Expo Connect
DESCRIPTION:As well as the physical CPhI & P-MEC China 2020 show that will take place in Shanghai from 16th – 18th December\, a digital extension of the event – known as “Virtual Expo Connect” – will take place online from November 18th – December 18th\, allowing you to do business in China\, no matter your location. The hybrid “Virtual Expo Connect” offers an online alternative for international visitors unable to travel to the physical show in China due to travel restrictions\, adding valued services and infinite opportunities to connect\, learn\, trade and grow. \nCPhI & P-MEC China Virtual Expo Connect\nA hybrid offline-2-online platform for global pharma professionals\nNov 18 – Dec 18\, 2020 \nTo know more about CPhI & P-MEC China Virtual Expo Connect please click here.
URL:https://www.pharmajournalist.com/event/cphi-p-mec-china-virtual-expo-connect/
LOCATION:Virtual Event powered by CPhI China & Pharmasources.com
CATEGORIES:e
ORGANIZER;CN="CPhI China & Pharmasources.com":MAILTO:yingqi.shi@imsinoexpo.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20201130
DTEND;VALUE=DATE:20201204
DTSTAMP:20260515T132444
CREATED:20200715T082010Z
LAST-MODIFIED:20200817T082502Z
UID:26329-1606694400-1607039999@www.pharmajournalist.com
SUMMARY:2nd Annual Gene Therapy Analytical Development | Running Digitally for 2020
DESCRIPTION:Optimizing Analytical Methods to Guarantee Safe\, High Quality\, Consistent & Efficacious Gene Therapy Products \nIn the context of rapid gene therapy progress and mounting regulatory scrutiny\, the 2nd Annual Gene Therapy Analytical Development Summit will virtually unite large pharma and innovative biotechs to discuss the full and comprehensive range of analytical tools required to guarantee the consistency\, quality and safety of gene therapy products. \n \nFocused specifically on addressing the unique analytical challenges posed by gene therapy vectors\, this technical scientific conference will unite the Analytical Development\, QC\, CMC\, and Process Development leaders grappling with these challenges first-hand. \nIncorporating tracks taking a deep dive into bioassays\, molecular biology\, and analytical chemistry\, this is your opportunity to gain extensive technical information enabling you to solve the exact challenges you’re encountering. Enhance your existing analytical methods and explore innovative novel tools to support safe and effective gene therapy development. \nTo know more about 2nd Annual Gene Therapy Analytical Development please click here.
URL:https://www.pharmajournalist.com/event/2nd-annual-gene-therapy-analytical-development/
LOCATION:Virtual Event
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20201201
DTEND;VALUE=DATE:20201204
DTSTAMP:20260515T132444
CREATED:20200826T084509Z
LAST-MODIFIED:20200826T093822Z
UID:26843-1606780800-1607039999@www.pharmajournalist.com
SUMMARY:2nd RNA Editing Summit 2020
DESCRIPTION:RNA Editing is reaching an inflection point and is rapidly being discussed\, invested in and adopted by the industry. \nThis year\, in an all new digital format\, the timely 2nd RNA Editing Summit returns as the only industry led meeting showcasing the recent developments of RNA editing mechanisms and dedicated to realizing the research and therapeutic opportunity of RNA editing as quickly as possible. \n \nThis meeting offers a wealth of relevant content covering everything from basic RNA biology and the fundamentals of RNA editing through to mitigating against off target activity to the plethora of clinical applications. \nJoin industry leaders from the likes of InsideOutBio\, Edigene\, Locano Bio and more to: \n\nHear the current strategies of site directed RNA editing from A – I to C – U to CRISPR based\nUnderstand how to mitigate off target-activity without critically effecting the efficiency of the on target edit in the transcript\nEnsure the safety and stability of your edit whilst maintaining efficiency and safe guard against potential toxic events\nAssess how to develop RNA editing technologies in preclinical models to ensure the system works as intended in the human body\nDelve into the different delivery mechanisms available to ensure the protein molecules that do the editing make it into the cells\nIdentify the latest clinical applications of RNA Editing\, reviewing the structures and functions of ADARs\, CRISPR CAS 13\, APOBEC and their involvements in human diseases\n\nTo know more about 2nd RNA Editing Summit 2020 please click here.
URL:https://www.pharmajournalist.com/event/2nd-rna-editing-summit-2020/
LOCATION:Virtual Event
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20201201
DTEND;VALUE=DATE:20201203
DTSTAMP:20260515T132444
CREATED:20200930T082606Z
LAST-MODIFIED:20200930T082606Z
UID:27304-1606780800-1606953599@www.pharmajournalist.com
SUMMARY:Neuromuscular Drug Development Summit
DESCRIPTION:Validate Clinically Meaningful Endpoints\, Optimize Clinical Trial Design & Compare & Contrast Diverse Approaches to Accelerate the Discovery & Development of Meaningful Treatments for Patients in Need \n \nThe 3rd Neuromuscular Drug Development  Summit presents a unique opportunity to: \n\nUncover the right outcome measures to use in your clinical trial and discover how to establish clinical meaningfulness with Biogen\nHear approaches to optimizing therapeutic efficacy in SMA\, an innovative approach to trial design for real world SMA population and how combinatorial treatments may improve SMA treatment outcomes with Roche\, PTC Therapeutics and John Hopkins University School of Medicine\nAssess emerging neurophysiological methods for more quantitative\, faster readouts and the need to explore digital capture tools to improve therapeutic R&D with Harvard Medical School and the Parent Project Muscular Dystrophy (PPMD)\nDissect various dosing strategies and discuss how to demonstrate a clear mechanistic route between dose\, mechanisms of action and endpoints with NMD Pharma and Argenx\nEvaluate the role of biomarkers\, how regulatory agencies approach the integration of biomarkers in clinical trials and biomarker outcome measures outside dystrophin with ReveraGen Biopharma and the Critical Path Institut\nHear how Avidity Biosciences are developing an oligonucleotide antibody conjugate for the treatment of DM1\n\nUniting drug developers and academics from all corners of the world\, the virtual Neuromuscular Drug Development Summit is your opportunity to discuss recent advances in this fast-evolving field\, convey lessons learned and network to build long lasting partnerships.
URL:https://www.pharmajournalist.com/event/neuromuscular-drug-development-summit/
LOCATION:Virtual Event
ORGANIZER;CN="Hansonwade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20201202
DTEND;VALUE=DATE:20201204
DTSTAMP:20260515T132444
CREATED:20200423T111553Z
LAST-MODIFIED:20200423T111553Z
UID:25220-1606867200-1607039999@www.pharmajournalist.com
SUMMARY:7th Microbiome & Probiotics R&D & Business Collaboration Forum: Europe
DESCRIPTION:In response to COVID-19\, this meeting will be hosted online using the latest digital technology. Network with your peers\, ask questions of the speakers\, and meet with the sponsors from the safety of your home or office. \nThis forum has a long-standing reputation for bringing together leading academic and industry microbiome researchers. Presentations will feature the latest research into the human microbiome as well as effective business and commercialization strategies for new products. \nTopics covered on the agenda include: \n\nIBD\, Colitis\, and Metabolic Diseases\nGut-brain axis\nWomen’s health\nSkin & Cosmeceuticals\nPersonalized nutrition\nBusiness Collaboration – Regulations & Investment\nProbiotics & Prebiotics\nRoundtable discussions\n\nWith dedicated space in the schedule to network\, this conference is the ideal forum to share knowledge and build partnerships. \nVisit the event page to download the full agenda.
URL:https://www.pharmajournalist.com/event/7th-microbiome-probiotics-rd-business-collaboration-forum-europe/
LOCATION:Rotterdam\, The Netherlands
ORGANIZER;CN="Global Engage Ltd.":MAILTO:info@globalengage.co.uk
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20201202
DTEND;VALUE=DATE:20201204
DTSTAMP:20260515T132444
CREATED:20200828T083254Z
LAST-MODIFIED:20200828T083616Z
UID:26875-1606867200-1607039999@www.pharmajournalist.com
SUMMARY:Clinically Validated Digital Therapeutics Summit
DESCRIPTION:As the world opens up to digital health\, now is the time to design\, develop & deliver clinically validated digital therapeutics to patients in need. Back for its 3rd year\, the Clinically Validated Digital Therapeutics Summit will unite more stakeholders than ever before. Explore newcomers in the world of DTx\, showcasing never before shared case studies. This meeting will solely focus on the actionable uses of digital therapeutics to deliver radically improved patient outcomes. \nIntegrating brand new lessons learned from the COVID 19 pandemic\, the 2020 summit will drive the DTx industry forward with case studies that tackle a multitude of disease areas and therapeutic modalities\, from prescription and chronic disease management to care bundles\, concomitant therapy and preventive medicine. Covering the full spectrum\, the 2020 summit will address challenges around clinical trials\, regulatory approval\, reimbursement and value application in healthcare. \nView the Full Event Guide Here.
URL:https://www.pharmajournalist.com/event/clinically-validated-digital-therapeutics-summit/
LOCATION:Virtual Event
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20201203
DTEND;VALUE=DATE:20201205
DTSTAMP:20260515T132444
CREATED:20200423T112329Z
LAST-MODIFIED:20200605T110454Z
UID:25224-1606953600-1607126399@www.pharmajournalist.com
SUMMARY:7th Digital Pathology & AI Congress: Europe
DESCRIPTION:This meeting has a reputation for providing an outstanding networking experience in which you can discover how to effectively harness gains such as reducing lab costs\, improving links between other laboratories & scientists and minimizing human error. \n \nOver two days you will discover more about the latest advances and applications of digital pathology\, including: \n\nHow artificial intelligence and machine learning is being applied to primary diagnosis and clinical research.\nHow the image-based information environment is transforming the laboratory.\nAI for image analysis and advancements in imaging.\nComputational pathology and AI.\nImplementation: practicalities and costs.\nPharma and industry case studies.\n\nWith dedicated space in the schedule to network\, this conference is the ideal forum to share knowledge and build partnerships. \nVisit the event page to download the full agenda.
URL:https://www.pharmajournalist.com/event/7th-digital-pathology-ai-congress-europe/
LOCATION:London\, UK
ORGANIZER;CN="Global Engage Ltd.":MAILTO:info@globalengage.co.uk
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20201207
DTEND;VALUE=DATE:20201211
DTSTAMP:20260515T132444
CREATED:20200217T121202Z
LAST-MODIFIED:20201123T131643Z
UID:24217-1607299200-1607644799@www.pharmajournalist.com
SUMMARY:BioFIT 2020
DESCRIPTION:Come and join us online for the 9th edition of BioFIT\, from the 7th to the 10th of December 2020! \nWith the highest attending rate of TTOs\, research institutes and academia together with big pharma\, emerging and small biotech\, diagnostics companies\, pre-seed / seed / Series A investors\, BioFIT is the leading partnering event in Europe for technology transfer\, academia-industry collaborations and early-stage innovation deals in the field of Life Sciences. BioFIT is also the European marketplace for pre-seed\, seed and Series A investment in Life Sciences. \n \nKEY FIGURES: \n\n1\,400+ delegates\n900+ organisations\n40+ countries represented\n1\,000 deals generated in 2017\n\nINSIDE THE EVENT: \n\nA business convention with pre-qualified one-to-one meetings\nConferences and roundtable discussions\nOral presentations of start-ups and licensing opportunities stemming from academia\nAn exhibition area\nInformal networking evenings\n\nAcross these 4 days of event\, you will be able to e-meet and network with these attendees from the comfort of your home office. The one-to-one partnering meetings will be possible 24H a day. \nYou will also have access\, for the conferences and the pitch sessions\, to a mix of live and on-demand content during those 4 days and available for 30 days afterwards; and you will also have the opportunity to debate with the speakers and pitchers via interactive online chats. \nWebsite: www.biofit-event.com \nRegistration: www.biofit-event.com/registration-for-biofit/ \nContact: msatola@eurasante.com
URL:https://www.pharmajournalist.com/event/biofit-2020/
LOCATION:Virtual Event
ORGANIZER;CN="Eurasant%C3%A9%2C Clubster NHL%2C BioValley France and Eurobiomed":MAILTO:msatola@eurasante.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20201208
DTEND;VALUE=DATE:20201211
DTSTAMP:20260515T132444
CREATED:20200817T090658Z
LAST-MODIFIED:20200817T090658Z
UID:26779-1607385600-1607644799@www.pharmajournalist.com
SUMMARY:2nd Annual Gene Therapy for Neurological Disorders | Running Digitally for 2020
DESCRIPTION:Revolutionize the Development & Delivery of Neurological Gene Therapies  \nReturning this year as a digital meeting with an agenda designed with the field’s thought-leaders including Pfizer\, Biogen\, Voyager and Novartis\, the 2nd Annual Gene Therapy for Neurological Disorders is the industry’s only meeting dedicated to solving your translational drug development challenges\, enabling you to accelerate the development of your neurological gene therapy candidate. \nDon’t get left behind. Attend this meeting to transform gene therapy delivery to the CNS\, optimize translational modelling approaches and discover targeted\, efficacious\, and safe vectors to revolutionize the treatment of neurological disorders. \nTo learn more about Gene Therapy for Neurological Disorders please click here: https://ter.li/c610sy
URL:https://www.pharmajournalist.com/event/2nd-annual-gene-therapy-for-neurological-disorders-running-digitally-for-2020/
LOCATION:Vitual Event
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20201208
DTEND;VALUE=DATE:20201211
DTSTAMP:20260515T132444
CREATED:20200819T090705Z
LAST-MODIFIED:20200819T090705Z
UID:26807-1607385600-1607644799@www.pharmajournalist.com
SUMMARY:3rd RNA-Targeted Drug Discovery Summit
DESCRIPTION:The 3rd RNA- Targeted Drug Discovery Summit returns as the most comprehensive and definitive event for the RNA targeting small molecule community to not only address key challenges of the field\, such as successful determination and prediction of RNA structure and role in disease\, but also to drive forward optimized strategies to improve target selection and gain pre-clinical proof of concept to drive the field forward towards translation into clinical development. \n \nWith numerous approaches emerging to demonstrate genuine viability in directly or indirectly targeting RNA with small molecules\, join leading biopharmaceutical directors\, VPs and C-level executives at the 3rd RNA- Targeted Drug Discovery Summit – your premier industry and translational focused conference dedicated to advancing pioneering RNA biology and drug discovery into a blockbuster RNA targeting small molecule therapeutic approach that improves patient outcomes. \nThe world of drug discovery and chemical probes is still protein-centric and developing highly selective small molecules targeting RNA is often considered to be an insurmountable challenge. This view is now changing given the recent progress and scientific breakthroughs in understanding the fundamental biology and function of RNA\, opening the door to RNA targeted small molecule drug discovery. \n  \n  \n\nExplore how to optimize medicinal chemistry insights & RNA biology to enhance robust translation with The Scripps Research Institute\, Anima Biotech & Arrakis Therapeutics\n\n  \n\nSuccessfully target RNA via interfering with RNA-protein interactions/ Epitranscriptomics with insights from Storm Therapeutics\, Accent Therapeutics & Saverna Therapeutics\n\n  \n\nExpand your knowledge of RNA structure\, function & role in disease with insights from Yale University\, H3 Biomedicine & Whitehead Institute for Biomedical Research\n\n  \n\nAdvance identification & validation of viable RNA target sites for therapeutic intervention with insights from PTC Therapeutics & Duke University\n\n  \n\nOvercome binding\, selectivity & drug-like challenges of small molecules targeting RNA with insights from Roche\, University of California San Diego & Novartis\n\n \nTo know more about 3rd RNA-Targeted Drug Discovery Summit please click here.
URL:https://www.pharmajournalist.com/event/3rd-rna-targeted-drug-discovery-summit/
LOCATION:Digital Event
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20201208
DTEND;VALUE=DATE:20201210
DTSTAMP:20260515T132444
CREATED:20201020T131537Z
LAST-MODIFIED:20201020T131537Z
UID:27562-1607385600-1607558399@www.pharmajournalist.com
SUMMARY:Decentralized Clinical Trails Summit
DESCRIPTION:Strengthen Your Operational and Compliance Protocols to Accelerate Technology-Enabled\, Patient-Centric\, and Cost-Efficient Decentralized Clinical Trials \nWith the potential to improve recruitment rates\, simplify compliance\, reduce drop-out rates\, and speed-up your product’s time to market\, decentralized clinical trials represent an opportunity to rethink and refresh how research studies are conducted\, while keeping the patient at the heart of all trials. \n \nDespite this\, only a fraction of clinical trials are currently run as hybrid of virtual models. This is about to change. The age of decentralized clinical trials is here\, and keeping pace with the rest of the industry means preparing your internal processes for the change. \nCreated in conjunction with clinical trial leaders from big and small pharma\,  forward thinking  academics\, and research institutes\, the programme for this year’s Decentralized Clinical summit has been designed to help you to develop the toolkit you need to run successful decentralised trials. Join over 100+ peers this December to tackle issues such as: using digital tools and wearables\, maintaining data quality and integrity\, simplifying e-consent\, optimising patient recruitment\, restructuring project teams\, rethinking trial design and undertaking study-model matching. \nTo know more about Decentralized Clinical Trails Summit please click here.
URL:https://www.pharmajournalist.com/event/decentralized-clinical-trails-summit/
LOCATION:Virtual Event
ORGANIZER;CN="Hansonwade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20201208
DTEND;VALUE=DATE:20201211
DTSTAMP:20260515T132444
CREATED:20201026T092432Z
LAST-MODIFIED:20201026T092432Z
UID:27669-1607385600-1607644799@www.pharmajournalist.com
SUMMARY:3rd Microbiome Movement – Skin Health & Dermatology Summit
DESCRIPTION:As the tools and technologies that are available to study the skin microbiome become cheaper and more accessible\, the fundamental mechanisms that link the skin microbiome with skin health are becoming stronger. The demand for skin microbiome products is advancing rapidly which is only being reflected in the increasing number of products on the market that claim to modulate the microbiome. \nDespite this growing opportunity\, there are still a number of basic and clinical science that need addressing to ensure that industry researchers are creating products that demonstrate true impact in patients and consumers. \n \nThe 3rd Microbiome Movement ­– Skin Health & Dermatology Summit returns to unite leaders from academia and industry to address the unique challenges that working within the skin microbiome possesses\, with the goal to accelerate microbiome-targeted therapeutics and cosmetics. \nWith discussions focusing on targeting the microbiome to treat inflammatory skin disease\, exploring how pre\, pro and post biotics can be optimized to improve skin health as well as a view into the regulatory and patent landscape; this opportunity is not to be missed. This is not to mention our new Pre-Conference Commercialization & Marketing Focus Day that will provide a deep dive into consumer education and product differentiation. \nTo know more about 3rd Microbiome Movement – Skin Health & Dermatology Summit please click here.
URL:https://www.pharmajournalist.com/event/3rd-microbiome-movement-skin-health-dermatology-summit/
LOCATION:Digital Event
ORGANIZER;CN="Hansonwade":MAILTO:info@microbiome-movement.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20201209
DTEND;VALUE=DATE:20201219
DTSTAMP:20260515T132444
CREATED:20191030T073844Z
LAST-MODIFIED:20200923T084604Z
UID:23096-1607472000-1608335999@www.pharmajournalist.com
SUMMARY:Medical Fair Asia 2020 Digital Edition
DESCRIPTION:MEDICAL FAIR ASIA 2020 Digital Edition is set to take place from 9 – 18 December 2020. The shift to a digital event for its 13th edition is in response to the dynamic situation of the COVID-19 pandemic\, where travel and physical restrictions are still in effect globally. \n \nAs the leading medical and healthcare exhibition in the region\, the well-established exhibition will feature the latest medical technology and innovations\, and healthcare equipment and supplies for the Hospital\, Diagnostics\, Pharmaceutical\, Medical & Rehabilitation sectors. \nMoving from in-person interactions at a physical trade event to making virtual connections anywhere in the world\, MEDICAL FAIR ASIA Digital Edition aims to deliver the onsite benefits of a trade fair but with all the convenience of an online experience. \nMEDICAL FAIR ASIA is organised by Messe Düsseldorf Asia\, the subsidiary of Messe Düsseldorf GmbH based in Germany and organiser of the world’s no. 1 medical fair – MEDICA. The exhibition is also a member of the MEDICAlliance\, the global network for medical trade fairs worldwide. \nFor more information about Medical Fair Asia 2020 and to register\, visit https://www.medicalfair-asia.com/
URL:https://www.pharmajournalist.com/event/medical-fair-asia-2020/
LOCATION:Virtual Event\, CA
ORGANIZER;CN="Messe Duesseldorf Asia":MAILTO:medicalfair-asia@mda.com.sg
END:VEVENT
END:VCALENDAR